The company is conducting small trials of its transcranial magnetic stimulation treatment on a range of neurological problems.
Brainsway Ltd. (TASE:BRIN) has released preliminary results of its Phase IIa trial for the use of its transcranial magnetic stimulation (TMS) to treat blepharospasm - involuntary blinking. The results showed improvement in both subjective feelings of blinking and in the blink reflex recovery curve and abnormal brainstem hyper-excitability tests.
The trial was conducted jointly with the US National Institute of Health unit National Institute of Neurological Disorders and Stroke. It included 12 patients. The trial is one of the series of fairly small effectiveness tests that Brainsway is conducting before deciding which larger and more expensive treatments to pursue at multiple medical centers.
There are a wide range of treatments for blepharospasm, ranging from food supplements, drug treatments, and surgery to paralyze the eyelid muscles. Brainsway believes that the results of the trial demonstrate that TMS corrects hyper-excitability of the brainstem.
Published by Globes [online], Israel business news - www.globes-online.com - on January 20, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008